key: cord-0684921-4ad723uu
authors: Skariyachan, Sinosh; Gopal, Dharshini; Chakrabarti, Shweta; Kempanna, Priya; Uttarkar, Akshay; Muddebihalkar, Aditi G.; Niranjan, Vidya
title: Structural and molecular basis of the interaction mechanism of selected drugs towards multiple targets of SARS-CoV-2 by molecular docking and dynamic simulation studies- Deciphering the scope of repurposed drugs
date: 2020-10-14
journal: Comput Biol Med
DOI: 10.1016/j.compbiomed.2020.104054
sha: ee568462a40b6467396c64c2836899fce31dd11d
doc_id: 684921
cord_uid: 4ad723uu

The repurposing of FDA approved drugs is presently receiving attention for COVID-19 drug discovery. Previous studies revealed the binding potential of several FDA-approved drugs towards specific targets of SARS-CoV-2; however, limited studies are focused on the structural and molecular basis of interaction of these drugs towards multiple targets of SARS-CoV-2. The present study aimed to predict the binding potential of six FDA drugs towards fifteen protein targets of SARS-CoV-2 and propose the structural and molecular basis of the interaction by molecular docking and dynamic simulation. Based on the literature survey, fifteen potential targets of SARS-CoV-2, and six FDA drugs (Chloroquine, Hydroxychloroquine, Favipiravir, Lopinavir, Remdesivir, and Ritonavir) were selected. The binding potential of individual drug towards the selected targets was predicted by molecular docking in comparison with the binding of the same drugs with their usual targets. The stabilities of the best-docked conformations were confirmed by molecular dynamic simulation and energy calculations. Among the selected drugs, Ritonavir and Lopinavir showed better binding towards the prioritized targets with minimum binding energy (kcal/mol), cluster-RMS, number of interacting residues, and stabilizing forces when compared with the binding of Chloroquine, Favipiravir, and Hydroxychloroquine, later drugs demonstrated better binding when compared to the binding with their usual targets. Remdesvir showed better binding to the prioritized targets in comparison with the binding of Chloroquine, Favipiravir, and Hydroxychloroquine, but showed lesser binding potential when compared to the interaction between Ritonavir and Lopinavir and the prioritized targets. The structural and molecular basis of interactions suggest that the FDA drugs can be repurposed towards multiple targets of SARS-CoV-2, and the present computational models provide insights on the scope of repurposed drugs against COVID-19.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been a threat across the 45 world. The epidemic caused by SARS-CoV and Middle East respiratory syndrome coronavirus 46 (MERS-CoV) was observed in 2003 [27] 6Y2E Free enzyme of the SARS-CoV-2 (2019-nCoV) main protease 244 Glu21, and Lys24 identified to be the interacting residues (Fig. 1e) . The interaction of the drug showed the binding energies of -5.6, -5.3 and -4.9 kcal/mol, respectively. Endoribonuclease 280 interacted with the drugs via Asn29 and Asn30 (Fig. 1m) . ADP ribose phosphatase interacted with the drugs at Leu126 and Phe156 (Fig. 1n) , and RNA binding protein interacted with the showed binding energies of -4.9 and -7.0kcal/mol respectively. Nsp10 interacted with the ligands 285 by the residues such as Gln4289, Thr4292, Cys4294, and Lys4296, and the interaction stabilized 286 by a hydrogen bond (Fig. 1p ). Nsp16 interacted with the drug by residues such as Leu6819, 287 Leu6820, Tyr7020, and Val7021 (Fig. 1q) . The accessory protein, orf7a (PDB: 6W37) interacted 288 with the drug, and the complex was showed binding energy of -5.0kcal/mol, and the residues 289 interacted were found to be Tyr25 and Phe31 (Fig. 1r ). The molecular docking studied revealed This study showed the probable structural biology mechanism of the interactions between

Chloroquine and potential targets of SARS-CoV-2 by molecular docking studies. residues Asp38, Ala42, Lys43, and Asp44 found to be the interacting residues of nsp7 (Fig. 2f) .

Tyr135 and Ser177 interacted with nsp8 by a hydrogen bond (Fig. 2g) , and Trp800 interacted 316 with nsp12 with the formation of a hydrogen bond (Fig. 2h ). Favipiravir interacted with PLpro at 317 Asp76, Arg82, Tyr154, Asn156, and the binding energy estimated to be -4.7kcal/mol (Fig. 2i ).

Similarly, the drug showed the binding with Mpro at Glu14, Gly15, Met17, and Ala70, and the 319 binding energy was estimated to be -4.7kcal/mol (Fig. 2j ). The C-terminal domain of 320 nucleocapsid protein (PDB: 6WJI) interacted with the drug (binding energy of -4.6kcal/mol) at interaction stabilized by a hydrogen bond at Ala256 (Fig. 2m) . Similarly, ADP ribose 329 phosphatase (nsp3) interacted with the drug at Lys31, Pro32, His86, Ala89, and Lys90 (Fig. 2n ).

RNA binding protein (nsp9) interacted with the drug at Ser14, Asn26, Asp27, Ala29, Asp48, and 331 the interaction was stabilized by a hydrogen bond at Ser14 (Fig. 2o) . The non-structural proteins docked against the drug revealed that the binding energies of -5.3kcal/mol and -6.3kcal/mol, 397 respectively. Tyr4280, Tyr4283, Ile4291, Thr4292, Arg4331, and Leu4328 were identified to be 398 the interacting residues in nsp10 (Fig. 3p) , and Arg6817, Met6818, Leu6819, Leu6820, Tyr7020, 399 and Val7021 were identified as the residues involved in binding with nsp16 (Fig. 3q) . The Lys102, Gly130, Ile131, and Phe132 and formed a hydrogen bond at Asn40 (binding energy -516 7.6kcal/mol) (Fig. 5n ). Nsp9 RNA binding protein interacted with the drug with the binding 517 energy of -6.4kcal/mol, and Met13, Arg40, Val42, Phe57, Ser60, Ile66, and Thr68 identified as 518 the major binding residues (Fig. 5o) . The drug interacted with the non-structural proteins such as 519 nsp10 (chain B) and nsp16 (chain A) and showed the binding energies of 7.1kcal/mol and 520 8.7kcal/mol, respectively. The major binding position in nsp10 observed to be Gln4306, Ile4308, 521 J o u r n a l P r e -p r o o f Phe4342, Asp4344, Thr4371, Gly4374, and a hydrogen bond formed at Val4369 (Fig. 5p) . The 522 drug interacted with nsp16 at Leu6820, Lys6822, Glu6940, Asn6941, His6972, and Tyr7020 523 (Fig. 5q) . The drug and orf7a interacted at Tyr25, Phe31 Pro33, and the interaction stabilized by 524 hydrogen bonds with the binding energy of -6.4kcal/mol (Fig. 5r) . His1058 (Fig. 6a) . The closed state of glycoprotein and drug complex were stabilized with the 559 binding energy of -7.2kcal/mol, and the major interacting residues identified to be Ser730, 560

Thr732, Phe782, Phe823, Val860, Pro863, Asp867, Ile870, Asn955, and His1058 in which 561

Asp867 formed a hydrogen bond with the drug (Fig. 6b) . The interaction of drug and post-fusion 562 and pre-fusion state of the target demonstrated the binding energies of -7.5 and -6.0kcal/mol, 563 respectively. Asn919, Gln920, Lys921, Asn928, Ile1198, Leu1200, and Gln1201 were the major 564 residues present at the binding of cavity post-fusion state (Fig. 6c) . Thr33, Phe59, Val289,

Leu293, Asp294, Lys300, and Asn606 were the major residues present at the binding site of the 566 pre-fusion state (Fig. 6d) . HR-2 domain of the S2 subunit, when docked with the drug, showed 567 the binding energy of -5.9kcal/mol and Asp17, Asn20, Glu21, and Lys24 identified to be the 568 major interacting residues (Fig. 6e) . Nsp7, nsp8, and nsp12 of RdRp demonstrated the binding 569 energies of -6.3, -6.5, and -7.3kcal/mol, respectively, when the drug interacted with the target.

The drug interacted with nsp7 at the position Thr9, Leu13, Phe49, Met52, Val53, Leu56, Val66, 571 and Ile68 (Fig. 6f) . The drug also interacted with nsp8 at the position Asn100, Pro121, Ala125,

Ala126, Lys127, Leu128, Met129, Val131, Tyr149, and Trp154 in which Asn100, Ala126, 573 Lys127, and Met129 formed hydrogen bonds with the ligand (Fig. 6g) . The drug binds with 574 Nsp12 at Tyr32, Lys47, Lys80, Tyr129, Asn138, Cys139, Thr141, and Thr710, in which Tyr129 575 formed a hydrogen bond with the drug (Fig. 6h) . The PLpro and Mpro demonstrated the binding 576 energies of -6.3 and -7.1kcal/mol, respectively when the drug interacted with Ritonavir. and Leu178, in which, Asp179 formed a hydrogen bond (Fig. 6i) domain with a hydrogen bond at Arg277 (Fig. 6k) . Gln161, Leu162, Gln164, Gly165, Thr166, 585 Thr167, Leu168, and Tyr173 of the N-terminal domain of the target acted as the major binding 586 residues in which Gln161 formed a hydrogen bond with the drug (Fig. 6l) . Endoribonuclease 587 nsp15, nsp3-ADP ribose phosphatase, and nsp9 of RNA binding protein were interacted with the 588 drug, and the complexes were exhibited the binding energies of -7.2, -6.7, and -6.3kcal/mol, 589 respectively. The major interacting residues with the ligand observed in the nsp15 were Ile27,

Ile28, Asn29, Asn30, Pro51, and Val52 (Fig. 6m) , the interacting residues present in the nsp3 591 identified to be Ile23, Val49, Leu126, Gly130, Ile131, Pro136, Phe156, Asp157, and Leu160 592 (Fig. 6n ) and the major interacting residues present in the nsp9 observed to be Arg40, Phe41, 593 Phe57, Ile66, Thr68, and Ile92 with hydrogen bond at Val92 (Fig. 6o) . When nsp10 (chain B) 594 and nsp16 (chain A) interacted with the drug, the complexes showed binding energies of -595 6.9kcal/mol and -7.7kcal/mol, respectively. Ile4308, Asn4338, Thr4364, Val4369, Thr4371, and 596 Trp4376 were the major interacting residues observed in the nsp10, and Asp4344 formed a 597 hydrogen bond with the drug (Fig. 6p) . The residues Gln6804, Gln6850, Asn6853, Thr6854, 598 Ser7041, Lys7047, Leu7050, Lys7051, and Arg7053 acts as major residues present at the 599 binding pocket of nsp16 (Fig. 6q) . The orf7a interacted with the drug at Ser22, Gly23, Glu26, 600 Gly27, Phe31, Pro33, and Phe50 by a hydrogen bond at Tyr25 (binding energy of -5.3kcal/mol) (Fig. 6r) Leu5, Leu23, Asp25, Thr26, Gly27, and Phe99 identified to be the interacting residues (Fig. 7d) . 

The molecular docking studies suggested that Remdesivir showed the best binding potential shown in Fig. 12 . The protein RMSD showed a fluctuation from 1.3 to 3.1Å, which was probably due to the drug molecule interacted with the target and caused conformational changes.

The RMSD values of the protein ranged from 2.4Å to 3.0Å. The protein fluctuated at C-and N-814 terminals with RMSF above 5.4Å. The other residues also showed fluctuation, RMSF ranged 815 between 1.2 and 3.6Å, is shown in Fig. 12b . The ligand RMSF fluctuated between the range 0.8 -816 4.3Å, probably due to the interactions between the receptor and the ligand (Fig. 12c) . Hydrogen 817 bonds, hydrophobic interactions, water bridges, and ionic bonds formed due to protein-drug 818 interaction are shown in Fig. 12d . The residues such as Asn6841, Asp6873, Asp6899, Asp6928, 819 and Tyr6930 were formed hydrogen bonds with the drug. Hydrophobic (Tyr6930), polar 820 (Asn6899), and positively charged interactions (Asp6873, Asp6897, and Asp6928) were 821 stabilized the protein-drug complex during MD simulation (Fig. 12e) . The protein-drug binding 822 in the MD simulation is shown in Fig. 12f . The residues such as Asp6873, Asp6897, Asp6899, Fig. 13a . The RMSD was 845 found to be 2.4 -4.8Å and was probably due to the conformational changes of the protein during 846 the binding. RMSF of the protein is estimated to be 0.8 -6.2Å (Fig. 13b) . The ligand RMS based virtual screening to screen therapeutic agents and provide insights towards COVID-19.

The protein targets of SARS-CoV-2 included were spike glycoproteins, RdRp, endoribonuclease, provides the interaction models of six drugs with each of the fifteen predicted targets of SARS- 

The drug screening against COVID-19 is a worldwide concern, and there are several attempts J o u r n a l P r e -p r o o f J o u r n a l P r e -p r o o f 

Insights into SARS-CoV-2 genome

Structural genomics approach

World Health Organization. WHO Coronavirus Disease (COVID-19)

Understanding SARS-CoV-2 endocytosis for COVID-19 drug repurposing

Fast Identification of Possible Drug Treatment of Coronavirus Disease-19

Journal of Chemical 993 Information and Modeling, Advance online publication

Breakthrough: Chloroquine phosphate has shown apparent 996 efficacy in treatment of COVID-19 associated pneumonia in clinical studies

Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting 1000 SARS-CoV-2 infection in vitro

A systematic review of 1002 lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for 1003 coronavirus disease-19 treatment option

The journey of remdesivir: from Ebola to 1006 COVID-19

Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome 1009 coronavirus 2 with high potency

First Case of 2019 Novel Coronavirus in the United States, The New 1015 England journal of Medicine

Experimental Treatment with Favipiravir for COVID-19: An Open-Label 1019

Remdesivir, lopinavir, emetine, and 1022 homoharringtonine inhibit SARS-CoV-2 replication in vitro

A Trial of Lopinavir-Ritonavir in Covid-19

The Protein Data Bank

Cryo-EM structure of the 2019-nCoV spike in the prefusion 1034 conformation

Inhibition of SARS-CoV-2 (previously 2019-nCoV) 1037 infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that 1038 harbors a high capacity to mediate membrane fusion

Crystal structure of HR2 domain of 2019-nCoV S2 subunit

& 1043 Z. Rao. Structure of the RNA-dependent RNA polymerase from COVID-19 virus

Center for Structural Genomics of Infectious Diseases 1047 (CSGID)

Structural insights of SARS-CoV-2 nucleocapsid protein RNA binding 1054 domain reveal potential unique drug targeting sites

Crystal Structure of C-terminal Dimerization Domain of Nucleocapsid Phosphoprotein 1057 from SARS-CoV-2

A. Joachimiak 1059 & Center for Structural Genomics of Infectious Diseases (CSGID). Crystal Structure of 1060 ADP ribose phosphatase of NSP3 from SARS CoV-2

Crystal Structure of NSP15 Endoribonuclease from SARS CoV-2

The crystal structure of 1066 Nsp9 replicase protein of COVID-19

Crystal Structure of NSP10 -NSP16 Complex from SARS-CoV-2

DrugBank 5.0: a major 1076 update to the DrugBank database for

AutoDock Vina: improving the speed and accuracy of docking 1079 with a new scoring function, efficient optimization, and multithreading

X-ray structure of glutathione S-transferase from the malarial parasite Plasmodium 1083 falciparum

ACE2 X-ray structures reveal a 1086 large hinge-bending motion important for inhibitor binding and catalysis

Structures of influenza A virus 1090 RNA polymerase offer insight into viral genome replication

GRL-09510, a Unique P2-Crown-Reports

X-ray crystal structure of the SARS Coronavirus 1099 main protease

Structure and mechanism of the complex between 1101 cytochrome P4503A4 and ritonavir

Electrostatics of 1106 nanosystems: application to microtubules and the ribosome

Open Source Drug Discovery Consortium, & A. Lynn

a GROMACS tool for high-throughput MM-PBSA calculations

GROMACS 4.5: a high-1113 throughput and highly parallel open source molecular simulation toolkit

The origin, transmission and clinical therapies on coronavirus disease 2019 1117 (COVID-19) outbreak -an update on the status